Narrow band imaging can reduce recurrence of bladder tumors

April 28, 2016

Research into bladder tumour surgery has found that using narrow band imaging can significantly reduce the risk of disease recurrence.

The results of the clinical trial, published in European Urology, compared two groups of bladder cancer patients who were due to undergo bladder tumour resection surgery.

Only 5.6% of low-risk patients in the narrow band imaging (NBI) facilitated surgery group experienced a recurrence of bladder tumours in the 12 months following surgery, compared to 27.3% in those who underwent conventional TURBT (trans urethral resection of bladder tumours) surgery.

According to the World Cancer Research Fund, bladder cancer is the ninth most common cancer in the world, with 430,000 new cases diagnosed in 2012.

For patients with early bladder cancer, a specialist will remove the tumours from the bladder lining using a thin telescope called a cystoscope.

The trial, co-ordinated by the Clinical Research Office of the Endourological Society (CROES, Amsterdam), recruited 965 patients from 16 countries to be randomised to either conventional "white light" TURBT or NBI-facilitated bladder tumour surgery.

Mr Richard Bryan, from the University of Birmingham, explained, "Narrow band imaging makes it easier to identify bladder tumours. It can detect small bladder tumours that might otherwise by overlooked by more conventional 'white light' cystoscopy."

Narrow band imaging technology (NBI) was developed by Olympus Medical Systems (Japan) and was first used for bladder cancer patients at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust in 2005.

Mr Bryan continued, "My colleague, Mike Wallace, and I immediately saw the potential of this technology. Now this potential has been confirmed by a large international randomised controlled trial, and the results can only be good news for bladder cancer patients worldwide."

Olympus stated, "We are pleased to see the widespread use of NBI globally, and have been delighted to support this trial in the bladder cancer setting. We will continue to work very closely with urologists to further understand their needs and challenges, and will strive to develop technologies such as NBI that could contribute to improving patient care across the globe."

On behalf of CROES, Professor Jean de la Rosette said, "Conducting a trial of this size across 16 countries has been a great achievement for CROES and the Trial Management Group. We appreciate the time and effort that urologists across the globe have committed to this study, and these results are just the start of the study outputs. We are extremely grateful to Olympus for their support from the outset - so often such technologies are not robustly assessed in this way, and this represents a breakthrough for urology and CROES."

University of Birmingham

Related Bladder Cancer Articles from Brightsurf:

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer.

Anthrax may be the next tool in the fight against bladder cancer
Researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors.

Effectiveness of a new bladder cancer treatment demonstrated
Demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment.

Lifting the lid on bladder cancer support
Bladder cancer is a painful and sometimes life-threatening condition that patients can find difficult to talk about, with many becoming homebound as they cope with debilitating side effects such as incontinence.

How genomics profiling can help identify the best treatment for bladder cancer
A new computational tool -- a single-patient classifier -- effectively enables physicians to assign a bladder cancer subtype to an individual patient's cancer using that patient's genomic data.

Early menopause in smokers linked to bladder cancer
Research shows that experiencing menopause before the age of 45 is associated with a higher risk of bladder cancer.

Olfactory receptor as therapeutic target in bladder cancer
Researchers from Bochum have detected an olfactory receptor in the human bladder that might prove useful for bladder cancer therapy and diagnosis.

Bladder cancer model could pave the way for better drug efficacy studies
In the journal Cancer Research, UNC Lineberger Comprehensive Cancer Center researchers report they have developed a model of luminal bladder cancer, one of the two subtypes of advanced bladder cancer.

Genetic fixer-uppers may help predict bladder cancer prognosis
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers, who found that bladder cancer patients who had mutations in their ATM or RB1 genes -- proteins that help repair DNA damage when they're functioning normally -- tended not to live as long as patients without the mutations.

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer
Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology.

Read More: Bladder Cancer News and Bladder Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to